Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oculis Holding AG - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
OCS
Nasdaq
8731
https://oculis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oculis Holding AG
Oculis Publishes Invitation to the Annual General Meeting
- Apr 29th, 2024 8:05 pm
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
- Apr 22nd, 2024 1:27 pm
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
- Apr 11th, 2024 12:55 pm
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
- Apr 10th, 2024 10:30 am
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Apr 8th, 2024 10:30 am
Oculis to Participate at Upcoming April Investor Conferences
- Apr 4th, 2024 10:30 am
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
- Mar 18th, 2024 10:30 am
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
- Feb 28th, 2024 11:30 am
Oculis to Present at Upcoming February Investor Conferences
- Jan 29th, 2024 11:30 am
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
- Jan 22nd, 2024 11:30 am
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
- Dec 20th, 2023 11:30 am
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
- Dec 18th, 2023 11:30 am
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
- Dec 7th, 2023 11:30 am
Oculis Holding AG's (NASDAQ:OCS) top owners are individual investors with 48% stake, while 30% is held by private equity firms
- Nov 30th, 2023 11:56 am
Oculis Reports Q3 2023 Financial Results and Provides Company Update
- Nov 15th, 2023 11:30 am
Oculis to Present at Upcoming November Investor Conferences
- Nov 8th, 2023 11:30 am
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
- Nov 1st, 2023 10:30 am
Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress
- Oct 10th, 2023 10:30 am
Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
- Oct 5th, 2023 10:30 am
Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
- Sep 11th, 2023 10:30 am
Scroll